Ayurvedic Therapeutic Management of a Chronic Liver Disease With Progressed Chronic Liver Failure: A Clinical Case Study
DOI:
https://doi.org/10.48165/IRJAY.2026.90306Keywords:
Kamala, Pitta Dushti, Rakta Dushti, Ranjaka Pitta Dushti, Strotorodha and Yakrit VikaraAbstract
Chronic Liver Failure (CLF), evolving from long-standing Chronic Liver Disease (CLD), is a progressive condition marked by impaired liver function and systemic complications. In Ayurveda, it is understood as a manifestation of aggravated Pitta Dosha, particularly Ranjaka Pitta, resulting in Ama accumulation, Rakta Dushti, and Srotorodha, leading to conditions akin to Kamala, Yakritodar, or Kumbhak Kamala. This case report presents a 37-year-old male with CLF and associated features such as Mukha – Pada Shotha (facial and pedal oedema), Peeta Netra (jaundiced sclera), Daurbalya (weakness), and Vibandh (constipation). A 14-day integrative Ayurvedic protocol including Panchakarma therapies, classical formulations, and dietary modifications was administered. Marked clinical and biochemical improvements were observed post-treatment, including reduced bilirubin levels, improved haemoglobin, and relief in oedema and fatigue. The outcome highlights the efficacy of individualized Ayurvedic management in restoring Agni, correcting Pitta Dushti, and enhancing overall quality of life in CLF patients.
Downloads
References
Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on-chronic liver failure. J Hepatol. 2012;57(6):1336-1348.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024.
Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: An update. Gut. 2017;66(3):541-553.
Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382(22):2137-2145.
Kumari S, Laxmikant SD, B S, Khanal S. Efficacy of integrated Ayurveda treatment protocol in type 2 diabetes mellitus: A case report. J Ayurveda Integr Med. 2022;13(1):100512. doi:10.1016/j.jaim.2021.08.005.
Chattopadhyay K, Panniyammakal J, Biswas TK, Heinrich M, Lewis SA, Greenfield SM, et al. Effectiveness and safety of Ayurvedic medicines in type 2 diabetes mellitus management: A systematic review protocol. JBI Evid Synth. 2020;18(11):2380-2389. doi:10.11124/JBISRIR-D-19-00350.
Shukla V, Tripathi RD, editors. Charaka Samhita of Agnivesa. Vol. 1, Sutrasthana, Chapter 24, Verses 25-29. Delhi: Chaukhamba Sanskrit Pratishthan; 2013. p.325.
Tripathi B, editor. Madhavanidanam-Rogaviniscaya of Sri Madhavakara with Madhukosa Commentary by Vijayaraksita and Srikanthadatta. Vol. 1. Chapter 8. Varanasi: Chaukhamba Ayurvijnana Granthamala; p.322.
Patidar A, Mangal G, Sharma S. Matra Basti-Mode of action: A conceptual study. Int Res J Ayurveda Yoga. 2022;5:130-133. doi:10.47223/IRJAY.2022.5520.
Tonde SS. Review of Basti. World J Pharm Res. 2023;12(9):Article 30049. doi:10.20959/wjpr202319-30049.
Bagwari M, Gupta P, Goyal P, Bhawana, Mahajan K. Various types of Bahya Basti (Local Basti). J Ayurveda Integr Med Sci. 2024;9(7):276-284. doi:10.21760/jaims.9.7.43.
Rawat V, Kumar V, Verma S. Role of Shirodhara by Brahmi Taila in essential hypertension: A conceptual study. World J Pharm Med Res. 2020;6(10):154-158.
Sojitra D, Shukla H, Kanakhara B, Gosai R, Bhimani B. Lifestyle disorder related. World J Pharm Res. 2017;6(7). doi:10.20959/wjpr20177-8725.
Chowdhury BR. World's Best: The D.I.P. Diet. Available from: https://biswaroop.com/dipdiet/
Garud S, Chaudhary A, Kotecha M. Pathya Apathya–A peculiarity of Ayurveda. Int J Ayurvedic Herb Med. 2017;7(4):2635-2642. doi:10.18535/ijahm/v7i4.01.
Suman, Joshi NK. Millets: Forgotten grains with potential health benefits in Ayurveda with special reference to Kodrava. J Ayurveda Integr Med Sci. 2024;9(7):230-236. doi:10.21760/jaims.9.7.35.
Brodovicz KG, McNaughton K, Uemura N, Meininger G, Girman CJ, Steven H. Reliability and feasibility of methods to quantitatively assess peripheral oedema. Clin Med Res. 2009;7(1-2):21-31. doi:10.3121/cmr.2009.825.
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: A new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.
Larrey D. Drug-induced liver diseases. J Hepatol. 2000;32(Suppl 1):77-88. doi:10.1016/S0168-8278(00)80417-1.
Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: A bidirectional relationship. Lancet Gastroenterol Hepatol. 2021;6(10):747-757. doi:10.1016/S2468-1253(21)00169-2.
Panda AK, Sahoo PK, Nayak BP. Pathya and Apathya (wholesome and unwholesome diet and regimen) in Yakrit Kshaya (liver cirrhosis): A narrative review. J Ayurveda Integr Med Sci. 2020;5(5):419-425.
Patel MV, Patel KB, Gupta S, Michalsen A, Stapelfeldt E, Kessler CS. A complex multiherbal regimen based on Ayurveda medicine for the management of hepatic cirrhosis complicated by ascites: Nonrandomized, uncontrolled, single-group, open-label observational clinical study. Evid Based Complement Alternat Med. 2015;2015:613182. doi:10.1155/2015/613182.
Fernández T, Viñuela M, Vidal C, Barrera F. Lifestyle changes in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2022;17(2):e0263931. doi:10.1371/journal.pone.0263931.
Nigam R, Garg P. Antimicrobial studies on aqueous and ethanolic extract of root, stem and leaves of Phyllanthus niruri (Bhumi Amla): Hepatoprotective medicinal plant. Res J Pharm Technol. 2022;15(11). doi:10.52711/0974-360X.2022.00889.
Bhowmik D, Sampath KKP, Srivastava S, Paswan S, Sankar A. Traditional Indian herb Punarnava and its medicinal importance. J Pharmacogn Phytochem. 2012;1(1):52-58.
Solanki V, Pillai APG, Dave KK, De S. Pharmaceutical analysis of Dronpushpi (Leucas cephalotes). Pharma Sci Monit. 2017;8(2).
Taru P, Syed S, Kute P, Shikalgar M, Kad D, Gadakh A. Dashamool: A systematic overview. GIS Zeitschrift für Geoinformatik. 2022;9:1334-1345.
Bhattacharjee A, Shashidhara SC. Phytochemical and ethno-pharmacological profile of Crataeva nurvala Buch-Hum (Varuna): A review. Asian Pac J Trop Biomed. 2012;2(2):S1162-S1168.
Bhola S, Rao MP. Are Rasapanchaka physical effects or pharmacological effects? A detailed review. World J Pharm Res. 2016;5:404-415.
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024.
Tan CK, Goh GBB, Youn J, Yu JCK, Singh S. Public awareness and knowledge of liver health and diseases in Singapore. J Gastroenterol Hepatol. 2021;36(8):2135-2141. doi:10.1111/jgh.15496.
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 2021;3(4):100316. doi:10.1016/j.jhepr.2021.100316.
Snowdon VK, Guha N, Fallowfield JA. Noninvasive evaluation of portal hypertension: Emerging tools and techniques. Int J Hepatol. 2012;2012:691089. doi:10.1155/2012/691089.
Wright AS, Rikkers LF. Current management of portal hypertension. J Gastrointest Surg. 2005;9:992-1005.
Lu W, Qu J, Yan L, et al. Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: A systematic review and meta-analysis. Stem Cell Res Ther. 2023;14:301. doi:10.1186/s13287-023-03518-x.
Kibble H, Shawcross DL. The microbiome in portal hypertension. Clin Liver Dis (Hoboken). 2023;22(2):70-74. doi:10.1097/CLD.0000000000000051.
Bell AW. Personalized medicine for liver disease: From molecular mechanisms to potential targeted therapies. J Pers Med. 2022;12(5):663. doi:10.3390/jpm12050663.
Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal dysfunction in cirrhosis: Critical care management. Indian J Crit Care Med. [Year, volume, pages to be added if available].
